Conversely, immunotherapy based on immune checkpoint inhibition (ICI) has revolutionized cancer treatment and PD-1/PD-L1 axis is the target of different monoclonal antibodies approved for human use (Pembrolizumab and Nivolumab are approved anti-PD-1; Atezolizumab, Avelumab, Durvalumab are approved anti-PD-L1). Here, CD274 is linked to cancer.